I presume AZN took your rule of thumb into account when they projected the original anticipated end date. Or am I missing something? thanks for your thoughts. By the way trying to anticipate results from length of study has proven fatal in Biotech in the past. Is there reason to feel more strongly about time computations here? Thanks
Market Data 
Markets 
AI
